Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Glycobiology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FUT3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FUT3 ECD-His / Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View FUT3 Products |
| Gene Delivery | FUT3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and in vitro overexpression. |
View FUT3 Products |
| Benchmark Ab | Anti-FUT3 Recombinant Antibody Recombinant positive control for assay validation. |
View FUT3 Products |
| Validator | FUT3 siRNA Set For knockdown verification in functional glycan assays. |
View FUT3 Products |
| Related Target A | FUT6 Critical homolog for counter-screening to ensure FUT3-specific targeting. |
View FUT6 Products |
| Related Target B | MUC1 Major carrier glycoprotein of the FUT3-synthesized CA19-9 antigen in pancreatic cancer. |
View MUC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homology Off-Target Risks (FUT5/FUT6) | Human FUT3, FUT5, and FUT6 ortholog panels strictly verified by mass spectrometry. |
| Glycosylation-Dependent Activity | HEK293 mammalian expression host ensures native post-translational modifications. |
| Lack of Controls | Clinical-grade benchmark antibodies included for assay standardization. |
| False Positives in Knockdown | Sequence-verified siRNA pool included for target specificity validation. |
Live FUT3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FUT3 therapeutics is intensifying, with major players shifting focus from traditional mAbs to glycan-targeted therapeutics and diagnostic companion tools. As first-generation therapies targeting FUT3-derived glycans (such as CA19-9/sialyl Lewis A) reach advanced clinical stages, the next wave of R&D is targeting direct enzymatic inhibition of FUT3 to overcome metastasis and immune evasion in gastrointestinal malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies / ADCs | Mablink Bioscience, SillaJen | Pancreatic Cancer, Colorectal Cancer | Target Binding Assay (Need high-purity, natively glycosylated FUT3 ECD-Fc) |
| Small Molecule Inhibitors | Academic Consortia, Glycomimetics | Solid Tumors, Inflammatory Diseases | Enzymatic Activity & Selectivity Assay (Need FUT3 vs FUT5/FUT6 panels) |
| CAR-T / Cell Therapy | Maxocyte, BioNTech | Gastrointestinal Adenocarcinomas | Overexpression Cell Lines (Need high-titer FUT3 Lentivirus) |